Prestige Consumer Healthcare Closes LaCorium Deal, Prices $400M Notes
Prestige Consumer Healthcare finalizes its LaCorium Health acquisition, raises $400M in senior notes, and sets its Q1 FY2027 earnings date.
Prestige Consumer Healthcare (NYSE: PBH) executed three significant corporate moves in a single announcement on July 6, 2026, signaling an active capital deployment strategy as the Tarrytown, N.Y.-based over-the-counter health products company pushes into new territory. The company confirmed the completed acquisition of LaCorium Health, priced a $400 million private senior notes offering, and scheduled its first-quarter fiscal 2027 earnings release for August 6, 2026.
The closing of the LaCorium Health deal marks the formal completion of a transaction the company had previously flagged to investors. LaCorium expands Prestige's portfolio, though the financial terms of the acquisition were not disclosed in the announcement. The timing of the debt raise alongside the deal closing strongly suggests the $400 million senior notes offering was structured, at least in part, to finance the purchase — a common mechanism for mid-cap consumer health companies managing balance sheet flexibility after an acquisition.
Read more Solaris Energy Acquires GESA in Mixed Cash-and-Stock Deal →
The $400 million senior notes were priced as a private offering, meaning they were marketed to institutional investors rather than retail buyers, consistent with how Prestige has historically managed its debt capital stack. Investors will be watching whether the company addresses leverage guidance and integration timelines when it reports quarterly results in early August.
With an earnings date set for August 6, 2026, analysts and shareholders will have their first formal opportunity to assess how the LaCorium transaction and associated debt load factor into Prestige's forward outlook. The company has built its business model around acquiring and scaling niche consumer healthcare brands, making deal-driven updates to revenue guidance particularly consequential for the stock.
Continue reading at GlobalNewswire.
